» Articles » PMID: 30423049

Microbial Etiology and Prognostic Factors of Ventilator-associated Pneumonia: A Multicenter Retrospective Study in Shanghai

Overview
Journal Clin Infect Dis
Date 2018 Nov 14
PMID 30423049
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The microbial etiology and mortality risk factors of ventilator-associated pneumonia (VAP) have not been investigated extensively in Shanghai.

Methods: VAP cases were identified from the patients hospitalized during the period from 1 January 2013 to 30 December 2017 in Shanghai. The relevant data were reviewed and analyzed retrospectively.

Results: One hundred ninety-four VAP cases were included in this analysis. The overall mortality rate was 32.47%. The respiratory pathogens isolated from these patients included 212 bacterial strains and 54 fungal strains. The leading pathogens were Acinetobacter baumannii (33.96%), Klebsiella pneumoniae (23.58%), Pseudomonas aeruginosa (19.81%), and Staphylococcus aureus (7.08%). Candida colonization was associated with higher mortality of VAP patients compared to those without Candida colonization (45.45% vs 28.67%, P < .05). The VAP patients with Candida colonization also showed higher prevalence of P. aeruginosa, carbapenem-resistant P. aeruginosa (CRPA), K. pneumoniae, carbapenem-resistant K. pneumoniae (CRKP), A. baumannii, and carbapenem-resistant A. baumannii (CRAB) (P < .05). VAP nonsurvivors had higher prevalence of CRPA, K. pneumoniae, CRAB, and Candida than VAP survivors (P < .05). Multivariate analysis showed that prior antibiotic use was a significant risk factor for Candida colonization, while hypertension and length of hospital stay were significant risk factors of VAP mortality (P < .05).

Conclusions: The top pathogens of VAP patients in Shanghai tertiary teaching hospitals are A. baumannii, K. pneumoniae, and P. aeruginosa, with high prevalence of carbapenem resistance. Carbapenem-resistant bacterial pathogens and Candida may predict poor outcome.

Citing Articles

Ventilator-Associated Pneumonia After Cardiac Arrest and Prevention Strategies: A Narrative Review.

Shanmugavel Geetha H, Teo Y, Ravichandran S, Lal A Medicina (Kaunas). 2025; 61(1).

PMID: 39859060 PMC: 11767168. DOI: 10.3390/medicina61010078.


Clinical outcomes of antifungal therapy on Candida pulmonary colonisation in immunocompetent patients with invasive ventilation: a systematic review and meta-analysis.

Li L, Su S, Yang H, Xie H BMJ Open. 2024; 14(10):e083918.

PMID: 39438107 PMC: 11499771. DOI: 10.1136/bmjopen-2024-083918.


Positive sputum culture of spp as a risk factor for 30-day mortality in patients with hospital-acquired pneumonia: A propensity-score matched retrospective clinical study.

Han Y, Zuo Y, Luo Z, Ju M, Hua J, He B Chin Med J Pulm Crit Care Med. 2024; 1(2):113-118.

PMID: 39170823 PMC: 11332850. DOI: 10.1016/j.pccm.2023.04.005.


Novel Siderophore Cephalosporin and Combinations of Cephalosporins with β-Lactamase Inhibitors as an Advancement in Treatment of Ventilator-Associated Pneumonia.

Viscardi S, Topola E, Sobieraj J, Duda-Madej A Antibiotics (Basel). 2024; 13(5).

PMID: 38786173 PMC: 11117516. DOI: 10.3390/antibiotics13050445.


Distribution and antibacterial susceptibility pattern of isolated bacteria from endotracheal aspirates among ventilator-assisted pneumonia patients in Indonesia.

Andayani N, Mahdani W, Nisyra M, Agustin H Narra J. 2024; 3(1):e149.

PMID: 38450036 PMC: 10914143. DOI: 10.52225/narra.v3i1.149.